Supernus Pharmaceuticals, Inc. (0LB2.L)
USD 33.23
(3.01%)
USD 33.23
(3.01%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.31 Million USD | -97.83% |
| 2022 | 60.71 Million USD | 13.64% |
| 2021 | 53.42 Million USD | -57.92% |
| 2020 | 126.95 Million USD | 12.29% |
| 2019 | 113.05 Million USD | 1.86% |
| 2018 | 110.99 Million USD | 93.76% |
| 2017 | 57.28 Million USD | -37.2% |
| 2016 | 91.22 Million USD | 550.83% |
| 2015 | 14.01 Million USD | -29.47% |
| 2014 | 19.87 Million USD | 121.54% |
| 2013 | -92.27 Million USD | -99.36% |
| 2012 | -46.28 Million USD | -182.65% |
| 2011 | 56 Million USD | 245.6% |
| 2010 | -38.46 Million USD | -8461.52% |
| 2009 | 460 Thousand USD | 101.37% |
| 2008 | -33.48 Million USD | -93.83% |
| 2007 | -17.27 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 38.49 Million USD | 93.3% |
| 2024 Q2 | 19.91 Million USD | 15961.29% |
| 2024 Q1 | 124 Thousand USD | -89.45% |
| 2023 Q4 | 1.17 Million USD | 107.35% |
| 2023 Q3 | -15.97 Million USD | -1822.5% |
| 2023 Q1 | 16.94 Million USD | -33.49% |
| 2023 Q2 | -831 Thousand USD | -104.9% |
| 2023 FY | 1.31 Million USD | -97.83% |
| 2022 FY | 60.71 Million USD | 13.64% |
| 2022 Q4 | 25.48 Million USD | 1356.89% |
| 2022 Q2 | 7.86 Million USD | -69.3% |
| 2022 Q1 | 25.61 Million USD | 948.98% |
| 2022 Q3 | 1.74 Million USD | -77.76% |
| 2021 Q3 | 21.56 Million USD | -9.12% |
| 2021 Q1 | 5.69 Million USD | -81.49% |
| 2021 FY | 53.42 Million USD | -57.92% |
| 2021 Q2 | 23.72 Million USD | 316.68% |
| 2021 Q4 | 2.44 Million USD | -88.67% |
| 2020 Q3 | 39.99 Million USD | 15.37% |
| 2020 Q2 | 34.66 Million USD | 61.11% |
| 2020 Q1 | 21.51 Million USD | -35.05% |
| 2020 FY | 126.95 Million USD | 12.29% |
| 2020 Q4 | 30.76 Million USD | -23.07% |
| 2019 Q1 | 18.34 Million USD | -29.17% |
| 2019 Q3 | 28.86 Million USD | -11.82% |
| 2019 Q2 | 32.72 Million USD | 78.45% |
| 2019 Q4 | 33.12 Million USD | 14.79% |
| 2019 FY | 113.05 Million USD | 1.86% |
| 2018 FY | 110.99 Million USD | 93.76% |
| 2018 Q1 | 26.35 Million USD | 92.94% |
| 2018 Q2 | 30.73 Million USD | 16.64% |
| 2018 Q3 | 28.01 Million USD | -8.87% |
| 2018 Q4 | 25.89 Million USD | -7.56% |
| 2017 Q1 | 10.29 Million USD | -28.09% |
| 2017 Q3 | 15.96 Million USD | -8.1% |
| 2017 Q4 | 13.65 Million USD | -14.43% |
| 2017 FY | 57.28 Million USD | -37.2% |
| 2017 Q2 | 17.36 Million USD | 68.67% |
| 2016 Q3 | 61.82 Million USD | 503.12% |
| 2016 Q2 | 10.25 Million USD | 112.46% |
| 2016 Q1 | 4.82 Million USD | -29.78% |
| 2016 FY | 91.22 Million USD | 550.83% |
| 2016 Q4 | 14.31 Million USD | -76.84% |
| 2015 Q2 | 2.43 Million USD | 230.22% |
| 2015 Q3 | 3.91 Million USD | 60.69% |
| 2015 Q4 | 6.87 Million USD | 75.46% |
| 2015 FY | 14.01 Million USD | -29.47% |
| 2015 Q1 | 738 Thousand USD | -83.05% |
| 2014 Q4 | 4.35 Million USD | -84.37% |
| 2014 Q3 | 27.85 Million USD | 770.02% |
| 2014 Q2 | 3.2 Million USD | 120.6% |
| 2014 FY | 19.87 Million USD | 121.54% |
| 2014 Q1 | -15.54 Million USD | 30.63% |
| 2013 Q1 | -18.41 Million USD | -36.28% |
| 2013 Q3 | -24.09 Million USD | 11.92% |
| 2013 Q4 | -22.4 Million USD | 7.01% |
| 2013 FY | -92.27 Million USD | -99.36% |
| 2013 Q2 | -27.35 Million USD | -48.57% |
| 2012 Q2 | -10.01 Million USD | -7.93% |
| 2012 Q4 | -13.51 Million USD | -0.22% |
| 2012 FY | -46.28 Million USD | -182.65% |
| 2012 Q3 | -13.48 Million USD | -34.64% |
| 2012 Q1 | -9.27 Million USD | -111.32% |
| 2011 Q3 | -9.73 Million USD | -31.95% |
| 2011 Q4 | 81.98 Million USD | 942.26% |
| 2011 FY | 56 Million USD | 245.6% |
| 2011 Q2 | -7.37 Million USD | 33.23% |
| 2011 Q1 | -11.04 Million USD | -28.89% |
| 2010 FY | -38.46 Million USD | -8461.52% |
| 2010 Q4 | -8.57 Million USD | 0.0% |
| 2009 FY | 460 Thousand USD | 101.37% |
| 2009 Q4 | -8.18 Million USD | 0.0% |
| 2008 FY | -33.48 Million USD | -93.83% |
| 2007 FY | -17.27 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | 100.859% |
| Dynavax Technologies Corporation | -6.38 Million USD | 120.598% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 101.11% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 100.015% |
| Perrigo Company plc | -12.7 Million USD | 110.362% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 100.477% |
| Illumina, Inc. | -1.16 Billion USD | 100.113% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 99.978% |
| Nektar Therapeutics | -276.05 Million USD | 100.477% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 100.296% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 99.903% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 101.19% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 103.302% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 99.215% |
| Waters Corporation | 642.23 Million USD | 99.795% |
| Biogen Inc. | 1.16 Billion USD | 99.887% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 100.51% |
| Adicet Bio, Inc. | -142.65 Million USD | 100.922% |
| Evolus, Inc. | -61.68 Million USD | 102.133% |
| bluebird bio, Inc. | -211.91 Million USD | 100.621% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 101.487% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 100.629% |
| FibroGen, Inc. | -284.23 Million USD | 100.463% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 99.894% |
| Homology Medicines, Inc. | -53.74 Million USD | 102.449% |
| Geron Corporation | -184.12 Million USD | 100.715% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 100.299% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 102.95% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 100.868% |
| Myriad Genetics, Inc. | -112 Million USD | 101.175% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 99.967% |
| OPKO Health, Inc. | -188.86 Million USD | 100.697% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 101.532% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 100.273% |
| Zoetis Inc. | 2.34 Billion USD | 99.944% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 102.429% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 99.833% |
| Exelixis, Inc. | 207.76 Million USD | 99.367% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 99.964% |
| uniQure N.V. | -308.47 Million USD | 100.427% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 103.119% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 102.77% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 100.55% |
| Verastem, Inc. | -87.36 Million USD | 101.506% |
| Imunon, Inc. | -19.51 Million USD | 106.744% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 100.359% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 100.246% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 99.473% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 98.76% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 99.533% |
| TG Therapeutics, Inc. | 12.67 Million USD | 89.615% |
| Blueprint Medicines Corporation | -506.98 Million USD | 100.26% |
| Insmed Incorporated | -749.56 Million USD | 100.176% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 100.374% |
| Incyte Corporation | 597.59 Million USD | 99.78% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 100.173% |